Physician profile
Steven A Singer
NPI 1922078229
$3,242.41
in general payments reported to CMS, 2019-2025
47 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $275 · 2021: $264 · 2022: $257 · 2023: $729 · 2024: $738 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,101.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $387.06 | 2020-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $357.49 | 2023-2025 | |
| Amgen INC. | $354.90 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $192.57 | 2021-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $172.36 | 2019-2023 | Spravato |
| Astellas Pharma US INC | $168.38 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $114.45 | 2020-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $110.08 | 2019-2025 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $87.29 | 2022-2025 | Gardasil 9, Capvaxive, Belsomra |
| Boston Scientific Corporation | $83.59 | 2022-2025 | General - Therapies, Wavewriter Alpha Prime 16 |
| Novartis Pharmaceuticals Corporation | $68.32 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.31 | 2020-2023 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.96 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $59.34 | 2023-2024 | Nuedexta, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $56.32 | 2021-2024 | Eliquis |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $54.33 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $53.09 | 2024 | |
| Esperion Therapeutics, INC. | $51.30 | 2020-2023 | Nexletol |
| Exact Sciences Corporation | $48.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $42.58 | 2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $42.36 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Horizon Therapeutics Plc | $39.96 | 2019-2022 | |
| Seqirus USA INC | $39.34 | 2021-2025 | Flucelvax, Fluad |
| Ibsa Pharma INC. | $38.84 | 2021-2025 | Tirosint, Flector, Licart |
| Amarin Pharma, INC. | $38.22 | 2019 | |
| Sumitomo Pharma America, INC. | $35.70 | 2023-2025 | Gemtesa |
| Lucid Diagnostics INC. | $29.92 | 2022 | |
| Idorsia Pharmaceuticals US INC | $29.81 | 2023-2024 | Quviviq |
| Radius Health, INC. | $28.95 | 2023 | Tymlos |
| Eisai INC. | $28.31 | 2021 | |
| Edwards Lifesciences Corporation | $26.48 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Inogen, INC. | $25.00 | 2023 | Inogen |
| Biohaven Pharmaceutical Holding Company LTD. | $21.81 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.62 | 2020 | |
| Bausch Health US, LLC | $19.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.07 | 2025 | |
| Abiomed | $19.02 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.71 | 2025 | Trintellix |
| Nevro Corp. | $16.56 | 2023 | Senza |
| Sunovion Pharmaceuticals INC. | $16.51 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.30 | 2023 | Ztlido |
| Biotronik INC. | $14.84 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.57 | 2019 | |
| Shire North American Group INC | $14.54 | 2019 | |
| Therapeuticsmd, INC. | $14.45 | 2019 | |
| Adlon Therapeutics L.P. | $13.45 | 2021 | |
| Tactile Systems Technology INC | $12.83 | 2023 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.